Pharma manufacturer finds treasure in Boston biotech Aquatrove

The Australian sexual health manufacturer Sasmar Pharmaceuticals has bought out Boston-based biotech Aquatrove Biosciences as it looks to expand its portfolio and pipeline more deeply into reproductive health and fertility.

Under the terms of the agreement, Sasmar, through its Australian-based holding (its formal headquarters is in Belgium), has acquired all stock in the privately held Aquatrove in exchange for an upfront payment of cash--although the exact amount has been kept under wraps.

“Like many pharmaceutical companies Sasmar is seeking biotechnology acquisitions to bolster product pipelines,” Sasmar said in a statement.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

This investment is designed to strengthen its position in the OTC market in health, fertility and reproduction. The pharma co’s president and CEO, John-Michael Mancini, said: “The acquisition captures the capability and knowhow built up over many years by the specialized team at Aquatrove and facilitates the realization of our plans for growth moving forward.”

The two companies already have a long history, given that back in 2008, Sasmar first sold an Aquatrove-patented formulation on a lubricant designed to help reduce the risks to fertility while attempting to conceive.

- check out the release

Related Article:
Gilead steps in to replace AbbVie with $2B Galapagos collaboration

Read more on

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.